Full CoverageCompass psilocybin therapy shown to be effective in largest-ever study in depression
By Olivia Goldhill
Top news
Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle
By Josh Hardman
Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial
By Fiona Rutherford & Gerry Smith
Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed
By James Waldron
Breakthrough: First-Ever Phase 3 Psilocybin Trial Shows Powerful Depression Treatment Success
All coverage
Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression
By Tristan Cesar Manalac
atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say
By Angela Harmantas & Emily Jarvie
Psychedelic medicine stocks fall following Compass depression asset data (ATAI:NASDAQ)
By Jonathan Block, MPH
Compass Pathways drops despite hitting primary goal in psilocybin trial
By Emily Jarvie & Angela Harmantas
Updated: Compass claims Phase 3 win in depression for psilocybin drug, yet stock plummets
By Ayisha Sharma
Compass Pathways stock slip as psilocybin depression trial falls short of expectations
By Vatsala Gaur
Compass plummets as late-stage data on psychedelic asset for depression disappoints.
By Jonathan Block, MPH